Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Awad

Showing results (711-720 of 839) with videos related to

Pageof 84
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 10, 2018
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung CancerLorena Ostios-Garcia, Jennifer Faig, Giulia C Leonardi, et al.
JAMA Oncology|June 4, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-AnalysisAlessandro Di Federico, Samuele Compagno, Francesco Mantuano, et al.
JAMA Oncology|May 23, 2024
Body Composition in Advanced Non-Small Cell Lung Cancer Treated With ImmunotherapyTafadzwa L Chaunzwa, Jack M Qian, Qin Li, et al.
British Journal of Pharmacology|December 17, 2013
Identification of plumericin as a potent new inhibitor of the NF-κB pathway with anti-inflammatory activity in vitro and in vivoN Fakhrudin, B Waltenberger, M Cabaravdic, et al.
Plos One|October 17, 2013
Imbricaric acid and perlatolic acid: multi-targeting anti-inflammatory depsides from Cetrelia monachorumSarah K Oettl, Jana Gerstmeier, Shafaat Y Khan, et al.
JCO Precision Oncology|October 5, 2020
Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement AnalysisYi Lee, Evan W Clark, Marina S D Milan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerJustin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
Science Immunology|May 20, 2022
<i>Clostridium septicum</i> α-toxin activates the NLRP3 inflammasome by engaging GPI-anchored proteinsWeidong Jing, Jordan Lo Pilato, Callum Kay, et al.
Nature Cancer|January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysisMariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung CancerMark M Awad, Patrick M Forde, Nicolas Girard, et al.
Pageof 84

Showing results (711-720 of 839) with videos related to

Sort By:
Pageof 84
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 10, 2018
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung CancerLorena Ostios-Garcia, Jennifer Faig, Giulia C Leonardi, et al.
JAMA Oncology|June 4, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-AnalysisAlessandro Di Federico, Samuele Compagno, Francesco Mantuano, et al.
JAMA Oncology|May 23, 2024
Body Composition in Advanced Non-Small Cell Lung Cancer Treated With ImmunotherapyTafadzwa L Chaunzwa, Jack M Qian, Qin Li, et al.
British Journal of Pharmacology|December 17, 2013
Identification of plumericin as a potent new inhibitor of the NF-κB pathway with anti-inflammatory activity in vitro and in vivoN Fakhrudin, B Waltenberger, M Cabaravdic, et al.
Plos One|October 17, 2013
Imbricaric acid and perlatolic acid: multi-targeting anti-inflammatory depsides from Cetrelia monachorumSarah K Oettl, Jana Gerstmeier, Shafaat Y Khan, et al.
JCO Precision Oncology|October 5, 2020
Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement AnalysisYi Lee, Evan W Clark, Marina S D Milan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerJustin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
Science Immunology|May 20, 2022
<i>Clostridium septicum</i> α-toxin activates the NLRP3 inflammasome by engaging GPI-anchored proteinsWeidong Jing, Jordan Lo Pilato, Callum Kay, et al.
Nature Cancer|January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysisMariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung CancerMark M Awad, Patrick M Forde, Nicolas Girard, et al.
Pageof 84